Medicine Recommendations

For treating active psoriatic arthritis after inadequate response to DMARDs.

NICE TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA815

NICE TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

Administration in patients with respiratory conditions

Schizophrenia and other psychoses, mania, anxiety

Maintenance in schizophrenia and other psychoses

Rapid Tranquilisation

All licensed indications

Gender Dysphoria

Osteoarthritis

Psoriasis

Acute Gout (as per LSCMMG Guidelines)

For replacement therapy of adrenal insufficiency in children and adolescents (from birth to <18 years old)

Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Treatment of adrenal insufficiency in adults.

Treatment of mild non-infectious allergic or inflammatory conjunctival diseases

Treatment of essential thrombocythemia or polycythaemia vera with a high risk for thromboembolic complications

Psoriasis

The prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults suffering from symptomatic Sickle Cell Syndrome

Rheumatoid conditions, lupus erythematosus, dermatological conditions

Hypersalivation

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.